Needham & Company Reiterates a 'Buy' on Alnylam Pharmaceuticals (ALNY); Encouraging Clinical Data from ALN-TTR Program
Go back to Needham & Company Reiterates a 'Buy' on Alnylam Pharmaceuticals (ALNY); Encouraging Clinical Data from ALN-TTR Program| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 224.60 -4.05 (1.77%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $228.65 | 52 Week High | $109.10 | |||
| Open | $225.76 | 52 Week Low | $31.38 | |||
| Day High | $227.99 | P/E | N/A | |||
| Day Low | $222.12 | EPS | $-1.45 | |||
| Volume | 1,539,230 | |||||
